Ozempic vs. Wegovy: Key Differences Unveiled

Ozempic and Wegovy, both containing the active ingredient semaglutide, are GLP-1 receptor agonists with distinct profiles affecting diabetes and obesity treatment. Ozempic received FDA approval in 2017 primarily for type 2 diabetes management. In contrast, Wegovy was approved in 2021 for chronic weight management and later, in March 2024, received a cardiovascular indication. Wegovy offers a higher maximum weekly dosage of 2.4 mg compared to Ozempic's 2 mg. Clinical trials, such as STEP 1, demonstrated substantial weight loss with the 2.4 mg dose. Insurance coverage presents a significant disparity. Ozempic is generally covered for diabetes, but medications specifically for obesity, like Wegovy, encounter coverage obstacles. A 2025 KFF survey indicated that only 19% of large employers provided coverage for anti-obesity medications.